Literature DB >> 30591715

The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.

Andrew D Krystal1,2, Diego A Pizzagalli3, Sanjay J Mathew4, Gerard Sanacora5, Richard Keefe2, Allen Song2, Joseph Calabrese6, Andrew Goddard7, Wayne Goodman4, Sarah H Lisanby2,7, Moria Smoski2, Richard Weiner2, Dan Iosifescu8, John Nurnberger9, Steven Szabo2, James Murrough10, Anantha Shekhar9, William Potter7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30591715      PMCID： PMC6816017          DOI： 10.1038/nrd.2018.222

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  10 in total

1.  Research domain criteria (RDoC): toward a new classification framework for research on mental disorders.

Authors:  Thomas Insel; Bruce Cuthbert; Marjorie Garvey; Robert Heinssen; Daniel S Pine; Kevin Quinn; Charles Sanislow; Philip Wang
Journal:  Am J Psychiatry       Date:  2010-07       Impact factor: 18.112

2.  Two decades of new drug development for central nervous system disorders.

Authors:  Aaron S Kesselheim; Thomas J Hwang; Jessica M Franklin
Journal:  Nat Rev Drug Discov       Date:  2015-11-20       Impact factor: 84.694

Review 3.  Report on a multicenter fMRI quality assurance protocol.

Authors:  Lee Friedman; Gary H Glover
Journal:  J Magn Reson Imaging       Date:  2006-06       Impact factor: 4.813

4.  Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.

Authors:  Stephen L Lowe; Conrad J Wong; Jennifer Witcher; Celedon R Gonzales; Gemma L Dickinson; Robert L Bell; Linda Rorick-Kehn; MaryAnn Weller; Randall R Stoltz; Jane Royalty; Sitra Tauscher-Wisniewski
Journal:  J Clin Pharmacol       Date:  2014-03-26       Impact factor: 3.126

5.  Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram.

Authors:  Meline Stoy; Florian Schlagenhauf; Philipp Sterzer; Felix Bermpohl; Claudia Hägele; Kristina Suchotzki; Katharina Schmack; Jana Wrase; Roland Ricken; Brian Knutson; Mazda Adli; Michael Bauer; Andreas Heinz; Andreas Ströhle
Journal:  J Psychopharmacol       Date:  2011-09-17       Impact factor: 4.153

Review 6.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

7.  Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging.

Authors:  Ming-Qiang Zheng; Nabeel Nabulsi; Su Jin Kim; Giampaolo Tomasi; Shu-Fei Lin; Charles Mitch; Steven Quimby; Vanessa Barth; Karen Rash; John Masters; Antonio Navarro; Eric Seest; Evan D Morris; Richard E Carson; Yiyun Huang
Journal:  J Nucl Med       Date:  2013-01-25       Impact factor: 10.057

8.  Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release.

Authors:  Björn H Schott; Luciano Minuzzi; Ruth M Krebs; David Elmenhorst; Markus Lang; Oliver H Winz; Constanze I Seidenbecher; Heinz H Coenen; Hans-Jochen Heinze; Karl Zilles; Emrah Düzel; Andreas Bauer
Journal:  J Neurosci       Date:  2008-12-24       Impact factor: 6.167

Review 9.  Measuring drug-related receptor occupancy with positron emission tomography.

Authors:  Jan Passchier; Antony Gee; Antoon Willemsen; Willem Vaalburg; Aren van Waarde
Journal:  Methods       Date:  2002-07       Impact factor: 3.608

Review 10.  Biomarkers in development of psychotropic drugs.

Authors:  K Wiedemann
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986
  10 in total
  15 in total

1.  Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients.

Authors:  Joshua T Kantrowitz; Daniel C Javitt; Robert Freedman; Pejman Sehatpour; Lawrence S Kegeles; Marlene Carlson; Tarek Sobeih; Melanie M Wall; Tse-Hwei Choo; Blair Vail; Jack Grinband; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2020-02-03       Impact factor: 7.853

Review 2.  Device-Based Modulation of Neurocircuits as a Therapeutic for Psychiatric Disorders.

Authors:  Zhi-De Deng; Bruce Luber; Nicholas L Balderston; Melbaliz Velez Afanador; Michelle M Noh; Jeena Thomas; William C Altekruse; Shannon L Exley; Shriya Awasthi; Sarah H Lisanby
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-01-06       Impact factor: 13.820

Review 3.  Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation?

Authors:  Diego A Pizzagalli
Journal:  Am J Psychiatry       Date:  2022-07       Impact factor: 19.242

Review 4.  Predictive validity in drug discovery: what it is, why it matters and how to improve it.

Authors:  Jack W Scannell; James Bosley; John A Hickman; Gerard R Dawson; Hubert Truebel; Guilherme S Ferreira; Duncan Richards; J Mark Treherne
Journal:  Nat Rev Drug Discov       Date:  2022-10-04       Impact factor: 112.288

5.  Pharmacological Treatments for Anhedonia.

Authors:  Matthew E Klein; Ariela Buxbaum Grice; Sahil Sheth; Megan Go; James W Murrough
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 6.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

7.  Redirecting the revolution: new developments in drug development for psychiatry.

Authors:  Linda S Brady; William Z Potter; Joshua A Gordon
Journal:  Expert Opin Drug Discov       Date:  2019-09-23       Impact factor: 6.098

8.  A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.

Authors:  Andrew D Krystal; Diego A Pizzagalli; Moria Smoski; Sanjay J Mathew; John Nurnberger; Sarah H Lisanby; Dan Iosifescu; James W Murrough; Hongqiu Yang; Richard D Weiner; Joseph R Calabrese; Gerard Sanacora; Gretchen Hermes; Richard S E Keefe; Allen Song; Wayne Goodman; Steven T Szabo; Alexis E Whitton; Keming Gao; William Z Potter
Journal:  Nat Med       Date:  2020-03-30       Impact factor: 53.440

9.  Characterizing anhedonia: A systematic review of neuroimaging across the subtypes of reward processing deficits in depression.

Authors:  Alessandra Borsini; Amelia St John Wallis; Patricia Zunszain; Carmine Maria Pariante; Matthew J Kempton
Journal:  Cogn Affect Behav Neurosci       Date:  2020-08       Impact factor: 3.282

10.  Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study.

Authors:  Zhengchao Dong; Michael F Grunebaum; Martin J Lan; Vashti Wagner; Tse-Hwei Choo; Matthew S Milak; Tarek Sobeih; J John Mann; Joshua T Kantrowitz
Journal:  Front Psychiatry       Date:  2021-06-02       Impact factor: 4.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.